Active Ingredient: Aprocitentan
Aprocitentan is indicated for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Oral, 12.5 milligrams aprocitentan, once daily. The maximum allowed total dose is 25 milligrams aprocitentan daily.
The recommended dose is 12.5 mg orally once daily. The dose can be increased to 25 mg once daily for patients tolerating the 12.5 mg dose and in need of tighter blood pressure (BP) control.
If the patient misses a dose, the patient should be told to resume treatment the next day and not take two doses in the same day.
No dose adjustment is required in patients over the age of 65 years. There is limited clinical experience in patients over the age of 75 years.
Aprocitentan may be taken with or without food.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
